Hepatitis Drug
Development Market Research Report provides an overview of the
pipeline landscape for hepatitis infections. It provides comprehensive
information on the therapeutics under development and key players involved in
therapeutic development for hepatitis A, hepatitis B, hepatitis D and hepatitis
E, and features dormant and discontinued products.
Hepatitis refers to
inflammation of the liver and is most commonly caused by viral infections.
Hepatitis A and E are typically caused by ingestion of contaminated food or
water. Symptoms of hepatitis A infection include fatigue, nausea and vomiting,
loss of appetite, dark urine, muscle pain and yellowing of the skin and eyes.
Risk factors include a weakened
immune system and use of injected or non-injected illicit drugs. Symptoms of
hepatitis E include yellowing of the skin, dark urine, fever, fatigue, joint
pain, nausea, a loss of appetite and pain in the abdomen.
Hepatitis B and hepatitis D
infection typically occur as a result of contact with infected body fluids.
Transmission of hepatitis B can occur via sexual contact, injection drug use or
transfusions of contaminated blood and blood products. Hepatitis B virus can
cause an acute illness with symptoms that last several weeks, including
yellowing of the skin and eyes, dark urine, extreme fatigue, nausea, vomiting
and abdominal pain.
Hepatitis D infection only
occurs in persons previously infected with hepatitis B, as the hepatitis D
virus can only replicate in the presence of hepatitis B. The co-infection of
hepatitis B and hepatitis D is associated with greater disease severity than
hepatitis B infection alone.
Companies operating in this
pipeline space include Cadila Healthcare and Chongqing Zhifei Biological
Products.
The report also includes the
following details:-
- Which companies are the most
active within each pipeline?
- Which pharmaceutical
approaches are the most prominent at each stage of the pipeline and within each
indication?
- To what extent do
universities and institutions play a role within this pipeline, compared to
pharmaceutical companies?
- What are the most important
R&D milestones and data publications to have happened in this disease area?
- Understand the overall
pipeline, with an at-a-glance overview of all products in therapeutic
development for each indication
- Assess the products in
development in granular detail, with an up-to-date overview of each individual
pipeline program in each indication and a comprehensive picture of recent
updates and milestones for each
- Analyze the companies,
institutions and universities currently operating in the pipeline and the
products being fielded by each of these
- Understand the composition of
the pipeline in terms of molecule type, molecular target, mechanism of action
and route of administration
To know
more, click on the link below:
Related Report:
Contact Us:
Ken Research
Ankur Gupta, Head
Marketing & Communications
+91-9015378249
